279 related articles for article (PubMed ID: 30288349)
1. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion.
Ghose J; Viola D; Terrazas C; Caserta E; Troadec E; Khalife J; Gunes EG; Sanchez J; McDonald T; Marcucci G; Kaur B; Rosenzweig M; Keats J; Rosen S; Krishnan A; Satoskar AR; Hofmeister CC; Pichiorri F
Oncoimmunology; 2018; 7(10):e1486948. PubMed ID: 30288349
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.
Kim K; Phelps MA
Clin Pharmacokinet; 2023 Jun; 62(6):789-806. PubMed ID: 37129750
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma.
Sanchez L; Richter J; Cho HJ; Jagannath S; Madduri D; Parekh S; Richard S; Tam L; Verina D; Chari A
Ther Adv Hematol; 2021; 12():2040620720987075. PubMed ID: 33613930
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma.
Cho N; Ko S; Shokeen M
Mol Imaging Biol; 2021 Apr; 23(2):186-195. PubMed ID: 32964391
[TBL] [Abstract][Full Text] [Related]
6. Resolving the daratumumab interference with blood compatibility testing.
Chapuy CI; Nicholson RT; Aguad MD; Chapuy B; Laubach JP; Richardson PG; Doshi P; Kaufman RM
Transfusion; 2015 Jun; 55(6 Pt 2):1545-54. PubMed ID: 25764134
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.
Stocker N; Gaugler B; Ricard L; de Vassoigne F; Marjanovic Z; Mohty M; Malard F
Cancer Med; 2020 Mar; 9(6):2077-2084. PubMed ID: 31991058
[TBL] [Abstract][Full Text] [Related]
8. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.
Overdijk MB; Verploegen S; Bögels M; van Egmond M; Lammerts van Bueren JJ; Mutis T; Groen RW; Breij E; Martens AC; Bleeker WK; Parren PW
MAbs; 2015; 7(2):311-21. PubMed ID: 25760767
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.
Viola D; Dona A; Caserta E; Troadec E; Besi F; McDonald T; Ghoda L; Gunes EG; Sanchez JF; Khalife J; Martella M; Karanes C; Htut M; Wang X; Rosenzweig M; Chowdhury A; Sborov D; Miles RR; Yazaki PJ; Ebner T; Hofmeister CC; Forman SJ; Rosen ST; Marcucci G; Shively J; Keats JJ; Krishnan A; Pichiorri F
Leukemia; 2021 Jan; 35(1):189-200. PubMed ID: 32296125
[TBL] [Abstract][Full Text] [Related]
10. Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method).
Hosokawa M; Kashiwagi H; Nakayama K; Sakuragi M; Nakao M; Morikawa T; Kiyokawa T; Aochi H; Nagamine K; Shibayama H; Tomiyama Y
Transfusion; 2018 Dec; 58(12):3003-3013. PubMed ID: 30267414
[TBL] [Abstract][Full Text] [Related]
11. Potential role of daratumumab in the treatment of multiple myeloma.
Khagi Y; Mark TM
Onco Targets Ther; 2014; 7():1095-100. PubMed ID: 24971019
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab Interference in Pretransfusion Testing Is Overcome by Addition of Daratumumab Fab Fragments to Patients' Plasma.
Werle E; Ziebart J; Wasmund E; Eske-Pogodda K
Transfus Med Hemother; 2019 Dec; 46(6):423-430. PubMed ID: 31933572
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study.
Vitkon R; Netanely D; Levi S; Ziv-Baran T; Ben-Yzak R; Katz BZ; Benyamini N; Trestman S; Mittelman M; Cohen Y; Avivi I
Ther Adv Hematol; 2021; 12():20406207211035272. PubMed ID: 34377384
[TBL] [Abstract][Full Text] [Related]
14. Evolving Role of Daratumumab: From Backbencher to Frontline Agent.
Jain A; Ramasamy K
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):572-587. PubMed ID: 32331971
[TBL] [Abstract][Full Text] [Related]
15. Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study.
Vakili H; Koorse Germans S; Dong X; Kansagra A; Patel H; Muthukumar A; Hashim IA
Diagnostics (Basel); 2020 Apr; 10(4):. PubMed ID: 32295157
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab interference in flow cytometric anti-granulocyte antibody testing can be overcome using non-human blocking antibodies.
Baig NA; Dukek BA; Falbo DK; Wakefield LL; DiGuardo MA; Bobr A; Kreuter JD; Gandhi MJ
Vox Sang; 2021 Jan; 116(1):116-122. PubMed ID: 32797679
[TBL] [Abstract][Full Text] [Related]
17. Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay.
Rosenberg AS; Bainbridge S; Pahwa R; Jialal I
Clin Biochem; 2016 Oct; 49(15):1202-1204. PubMed ID: 27475249
[TBL] [Abstract][Full Text] [Related]
18. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
Zamagni E; Tacchetti P; Pantani L; Cavo M
Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
[TBL] [Abstract][Full Text] [Related]
20. Artifactual Kappa Light Chain Restriction of Marrow Hematogones: A Potential Diagnostic Pitfall in Minimal Residual Disease Assessment of Plasma Cell Myeloma Patients on Daratumumab.
Jiang XY; Luider J; Shameli A
Cytometry B Clin Cytom; 2020 Jan; 98(1):68-74. PubMed ID: 31313879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
